To advance a promising, small-molecule compound CRS0540 to IND filing and through phase I clinical studies.

Active Definitive Contract Awarded Last action

Contract number
75N93020C00020
Awardee
Awarding agency
Obligated
$22,028,937

Award facts

Opportunity
Contract value 81% obligated
  • $22,028,937.00 Current, with exercised options
  • $27,049,982.00 Potential, with all options
Completion date 96% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 12 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Boulder, CO 80301, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00016 $0
Funding Only Action P00015 $1,550,947
Other Administrative Action P00013 · Development of therapeutic products for antibiotic resistant bacteria $0
Funding Only Action P00012 · To deobligate FY 2020 5TH year funds on line 1. To advance a promising, small-molecule compound CRS0540 to IND filing and through phase I clinical studies. -$1
Other Administrative Action P00011 $0
Other Administrative Action P00010 $1,580,854
Other Administrative Action P00009 $970,628
Other Administrative Action P00008 $2,665,864
Other Administrative Action P00007 $0
Funding Only Action P00006 $140,777
Exercise an Option P00005 $5,768,701
Exercise an Option P00004 $3,683,355
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $3,717,345
Show all 16

About this award

Written by GovTribe AI ·

The National Institute of Allergy and Infectious Diseases awarded a $27 million cost-plus-fixed-fee definitive contract to Crestone, Inc. to advance the small-molecule compound CRS0540 to investigational new drug filing and through Phase I clinical studies on July 1, 2020, with ultimate completion scheduled for January 31, 2027.

Place of performance is Boulder, Colorado. The work originated from a Broad Agency Announcement soliciting proposals for development of radiation and nuclear medical countermeasures, with up to $4 million per year available for one to two awards supporting research to develop safe and effective medical countermeasures to mitigate and treat tissue injuries from ionizing radiation exposure in radiological or nuclear incidents.

Service Contract Inventory data shows Crestone invoiced $3.2 million in FY2021 (7.7 FTEs, 16,075 contractor hours), $1.6 million in FY2022 (2.5 FTEs, 5,262 contractor hours), $5.7 million in FY2023 (16.0 FTEs, 33,386 contractor hours), $4.2 million in FY2024 (7.4 FTEs, 15,434 contractor hours), and $3.6 million in FY2025 (2.7 FTEs). Derived government-paid rates ranged from $170.10 per hour in FY2023 to $299.58 per hour in FY2022, trending upward across reported years. Crestone self-performed all reported work in FY2025 with no subcontractors.

Quick answers

Who was awarded contract 75N93020C00020?

75N93020C00020 was awarded to Crestone, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2020.

How much is contract 75N93020C00020 worth?

The government has obligated $22,028,937 on 75N93020C00020. Its potential value, with all options, is $27,049,982.

Was contract 75N93020C00020 competed?

The extent of competition for 75N93020C00020 was full and open competition. The government received 12 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login